menu
    • menu
    [{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Revilico","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Oxy210","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAX BioPharma \/ Revilico","highestDevelopmentStatusID":"4","companyTruncated":"MAX BioPharma \/ Revilico"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Oxysterol","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAX BioPharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"MAX BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxysterol","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAX BioPharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"MAX BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Metaba","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Oxysterol","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAX BioPharma \/ MAX BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"MAX BioPharma \/ MAX BioPharma"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Metaba","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAX BioPharma \/ Metaba","highestDevelopmentStatusID":"3","companyTruncated":"MAX BioPharma \/ Metaba"}]

    Find Clinical Drug Pipeline Developments & Deals by MAX BioPharma

    Menu

    MAX BioPharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxy210

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Revilico

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MAX and Revilico Announce Collaboration on Target Identification for Oxysterol Drugs

                            Details : Revilico brings an AI-enabled, end-to-end drug discovery platform integrating multi-omics data, structural modeling, and generative chemistry to optimize lead compounds like Oxy210.

                            Product Name : Oxy210

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 06, 2025

                            Lead Product(s) : Oxy210

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Revilico

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery Platform

                            Sponsor : Metaba

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metaba, MAX BioPharma Achieve Key Milestone on Next-Gen Oxysterol-Based Antibiotics

                            Details : Company is focused on developing oxysterol-based drug candidates targeting bacterial infections like tuberculosis, urinary tract infections, Lyme disease and MRSA.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery Platform

                            Sponsor : Metaba

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxysterol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MAX BioPharma Shares Updates On Anti-Inflammatory Oxysterol Drug Development

                            Details : Oxy210 (oxysterol) is being evaluating in the early-stage clinical trial studies for the treatment of patients suffering from non-alcoholic steatohepatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2024

                            Lead Product(s) : Oxysterol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxysterol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Recipient : Metaba

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies

                            Details : The collaboration focuses on developing Oxy210 (oxysterol), a small-molecule antifibrotic, evaluated in preclinical studies for non-alcoholic steatohepatitis and pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 26, 2024

                            Lead Product(s) : Oxysterol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Recipient : Metaba

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MAX BioPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxysterol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MAX BioPharma Announces Key Update to its Liver Fibrosis Program

                            Details : Oxy210 was found to significantly inhibit development of fibrosis in a humanized mouse model of NASH that involves progressive inflammation, fat deposition and fibrosis in the livers of these mice.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2020

                            Lead Product(s) : Oxysterol

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth